A Novel Index Consisting of Age, CA19-9, and Methylated Somatostatin Is Useful for Diagnosing Early Pancreatic Cancer.
A blood test combining age, CA19-9, and DNA methylation marks shows promise for detecting pancreatic cancer at earlier, more treatable stages.
This study developed and validated the ACAm-S index, a serum-based composite of age, CA19-9, and methylated somatostatin DNA, for diagnosing early pancreatic ductal adenocarcinoma. The high sensitivity for Stage I disease is particularly notable given PDAC's near-universal late-stage presentation and near-zero early-detection options.
What the study was
- Study design
- Case-control validation study
- Population
- 95 healthy subjects and 111 PDAC patients for ACAm-S index validation
- Sample size
- 206
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Cancer medicine
Why it surfaced
Novel composite biomarker achieving >85% sensitivity for Stage I PDAC—one of the highest-unmet-need cancers for early detection; requires independent validation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.